Gene therapy cocktail aims to wipe out bladder cancer before surgery
NCT ID NCT07332351
First seen Jan 12, 2026 · Last updated Apr 29, 2026 · Updated 16 times
Summary
This study tests whether adding a gene therapy (nadofaragene firadenovec) to standard chemotherapy and immunotherapy before bladder removal surgery can improve outcomes for people with muscle-invasive bladder cancer. About 33 adults will receive the combination treatment, then have their bladder removed to check if the cancer is gone. The goal is to see if this approach leads to a complete response, meaning no cancer remains in the removed bladder.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IIIA BLADDER CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.